DexTech Medical AB, Last day of trading in BTA

DexTech Medical AB (“DexTech” or the “Company”) hereby announces that the last day of trading in Paid Subscribed Shares (Sw. BTA) will be on 27 January 2022 and stop day will be on 31 January 2022.

During December 2021, DexTech conducted a rights issue, which provided the Company approximately SEK 46.35 million before deduction of transaction related costs. The rights issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and the last day of trading in BTA will be on 27 January 2022 and stop day will be on 31 January 2022. The shares are estimated to be delivered on the shareholder’s account on 2 February 2022.

Advisors
In connection with the rights issue, Sedermera Corporate Finance AB has been the financial advisor and Markets & Corporate Law Nordic AB has been the legal advisor. Nordic Issuing AB has been the issuing agent. Shark Communication AB has been the Company’s advisor regarding communication. 

For further information about the rights issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: [email protected]
www.sedermera.se

For more information about DexTech, please contact:

Gösta Lundgren – CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-mail: [email protected]

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical trial has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as treatment effect on patients who fail on existing drugs. DexTech's goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on Spotlight Stock Market.